Lipocine Inc. (Nasdaq: LPCN) reported positive results from a Phase 3 clinical study of its testosterone replacement LPCN 1021 sending the stock price soaring $2.33 to $7.55.
Lipocine reports upbeat study results
September 24, 2014 at 12:00 PM EDT